Lead Screening: Essential for Healthy Infants
The purpose of newborn blood screening is to identify health problems as early as possible, to limit the damage these issues might cause as much as possible, and to ensure babies receive the care they need as soon as possible. Currently, within 24 hours after birth, all babies born in the U.S. get a tiny needle prick on the bottom of their heel, and a few drops of their blood are collected onto filter-paper cards. Once the blood spots are dry, the cards go to a lab for analysis.
Today’s Dried Blood Spot [DBS] screening checks for about 50 treatable metabolic diseases, some of which require immediate treatment to keep babies healthy. But DBS doesn’t screen for any heavy-metal toxicity; in fact, all reference labs worldwide currently use #903 filter paper, which itself contains some heavy metals, so it can’t provide an accurate measure of blood lead levels.
EnMed’s EEvCarrier™ is the only screening tool using super-clean filter paper, uncontaminated by heavy metals – so it’s the only one that can detect blood lead levels with complete accuracy. And the one-drop blood sample it needs can be collected along with the same heel-stick as the DBS screening.
Our lead-screening solution provides every family with:
- the earliest possible detection of any blood lead level in newborn babies and infants – without a blood draw;
- the opportunity to prevent fetal abnormalities and limit developmental damage to babies’ brains and nervous systems due to lead poisoning; and
- the fastest possible health intervention, like chelation therapy, to remove lead from the blood and help ensure children can go on to lead healthy, productive lives.